Mizuho on Axsome Therapeutics (AXSM): 'recommend buying ahead of AXSM's 3Q print' Oct 21, 2026 05:26AM
RBC Capital Defending Axsome Therapeutics (AXSM): 'we would be buyers at these levels' Oct 14, 2026 05:58AM
3 high-conviction SMID-cap biotech stocks to buy: Jefferies Oct 1, 2026 03:00PM
Wells Fargo names 13 stocks as overweight tactical ideas Oct 1, 2026 06:30AM
H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM) Sep 25, 2026 06:46AM
View Older Stories

Sep 23, 2026 05:03AM Truist Securities Starts Axsome Therapeutics (AXSM) at Buy
Sep 21, 2026 07:02AM Survey finds Alzheimer's agitation often goes unrecognized until daily disruption
Aug 24, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Aug 12, 2026 06:38AM Axsome Therapeutics (AXSM) PT Raised to $316 at Mizuho
Aug 11, 2026 10:01AM Axsome Therapeutics (AXSM) PT Lowered to $279 at RBC Capital
Aug 11, 2026 07:11AM Axsome Therapeutics (AXSM) PT Raised to $268 at Needham
Aug 11, 2026 06:57AM Axsome Therapeutics (AXSM) PT Raised to $275 at Guggenheim
Aug 11, 2026 06:54AM Axsome Therapeutics (AXSM) PT Raised to $256 at Wells Fargo
Aug 10, 2026 07:39AM Axsome Therapeutics (AXSM) Misses Q2 EPS by 14c
Jul 20, 2026 04:13PM BMO Capital Starts Axsome Therapeutics (AXSM) at Outperform
Jul 16, 2026 06:47AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jul 14, 2026 07:55AM Piper Sandler Reiterates Overweight Rating on Axsome Therapeutics (AXSM)
Jul 8, 2026 06:40AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jun 17, 2026 09:13AM Axsome Therapeutics (AXSM) PT Raised to $300 at TD Cowen; 'Under-followed Pipeline Is Upside'
Jun 15, 2026 07:02AM Axsome Therapeutics presents sleep disorder data at SLEEP 2026 conference
Jun 11, 2026 05:34AM Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Jun 5, 2026 08:59AM Morgan Stanley tracks prescription trends for US neurology drugs
Jun 4, 2026 06:40AM H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jun 3, 2026 07:04AM Axsome settles SUNOSI patent litigation, allows generics starting 2040
Jun 1, 2026 07:03AM Axsome partners with Headache Alliance for migraine awareness month
May 5, 2026 06:05AM Axsome Therapeutics (AXSM) PT Raised to Street High $310 at Mizuho, Top Pick
May 5, 2026 04:20AM Axsome Therapeutics (AXSM) PT Raised to $300 at B.Riley
May 4, 2026 04:17PM Axsome Therapeutics (AXSM) PT Raised to $246 at Baird
May 4, 2026 04:07PM Axsome Therapeutics (AXSM) PT Raised to $302 at RBC Capital
May 4, 2026 03:19PM Axsome Therapeutics (AXSM) PT Raised to $280 at Oppenheimer
May 4, 2026 01:15PM Axsome Therapeutics (AXSM) PT Raised to $260 at Guggenheim
May 4, 2026 12:23PM Axsome Therapeutics (AXSM) PT Raised to $258 at Piper Sandler
May 4, 2026 12:06PM Axsome Therapeutics (AXSM) PT Raised to $275 at TD Cowen
May 4, 2026 07:33AM Axsome Therapeutics (AXSM) PT Raised to $270 at H.C. Wainwright
May 4, 2026 07:01AM Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c
May 1, 2026 11:25AM Axsome Therapeutics (AXSM) PT Raised to $255 at TD Cowen
Apr 30, 2026 05:15PM Axsome Therapeutics (AXSM) PT Raised to $250 at Oppenheimer
Apr 30, 2026 03:23PM Axsome Therapeutics (AXSM) PT Raised to $217 at Morgan Stanley
Apr 30, 2026 02:05PM Axsome Therapeutics (AXSM) Halted, News Pending
Apr 28, 2026 09:13AM Axsome Therapeutics (AXSM) PT Lowered to $228 at Mizuho
Apr 10, 2026 09:31AM Axsome Therapeutics (AXSM) PT Raised to $259 at UBS
Apr 2, 2026 08:28AM Piper Sandler on Axsome Therapeutics (AXSM): 'A High-Risk, High-Reward Opportunity'
Apr 1, 2026 05:41PM Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline
Apr 1, 2026 12:10PM Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline'
Apr 1, 2026 07:15AM William Blair Shuffles Analyst Conviction List for April 2026
Mar 27, 2026 08:47AM Mizuho stays Outperform rated on Axsome Therapeutics (AXSM) amid scripts decline
Mar 25, 2026 06:07AM Axsome Therapeutics (AXSM) PT Raised to $245 at Guggenheim
Mar 20, 2026 11:06AM Mizuho stays Outperform on Axsome Therapeutics (AXSM) as Auvelity Rx growth accelerates
Mar 13, 2026 06:02AM RBC Capital Defending on Axsome Therapeutics (AXSM)
Feb 24, 2026 10:32AM Axsome Therapeutics (AXSM) PT Raised to $251 at UBS
Feb 24, 2026 09:04AM Wolfe Research Starts Axsome Therapeutics (AXSM) at Outperform
Feb 24, 2026 08:51AM Axsome Therapeutics (AXSM) PT Raised to $222 at RBC Capital
Feb 24, 2026 05:40AM Axsome Therapeutics (AXSM) PT Raised to $220 at Guggenheim
Feb 23, 2026 12:32PM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Feb 23, 2026 12:17PM Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen
View Older Stories